HK1179959A1 - 光學活性二苄胺衍生物及其製備方法 - Google Patents

光學活性二苄胺衍生物及其製備方法

Info

Publication number
HK1179959A1
HK1179959A1 HK13107169.5A HK13107169A HK1179959A1 HK 1179959 A1 HK1179959 A1 HK 1179959A1 HK 13107169 A HK13107169 A HK 13107169A HK 1179959 A1 HK1179959 A1 HK 1179959A1
Authority
HK
Hong Kong
Prior art keywords
manufacturing
same
optically active
derivative
dibenzylamine derivative
Prior art date
Application number
HK13107169.5A
Other languages
English (en)
Inventor
Tadaaki Ohgiya
Takeshi Murakami
Katsutoshi Miyosawa
Kimiyuki Shibuya
Koichi Yamazaki
Taichi Kusakabe
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of HK1179959A1 publication Critical patent/HK1179959A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK13107169.5A 2010-06-04 2013-06-19 光學活性二苄胺衍生物及其製備方法 HK1179959A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010128585 2010-06-04
JP2010218299 2010-09-29
PCT/JP2011/062751 WO2011152508A1 (ja) 2010-06-04 2011-06-03 光学活性ジベンジルアミン誘導体及びその製造方法

Publications (1)

Publication Number Publication Date
HK1179959A1 true HK1179959A1 (zh) 2013-10-11

Family

ID=45066863

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13107169.5A HK1179959A1 (zh) 2010-06-04 2013-06-19 光學活性二苄胺衍生物及其製備方法

Country Status (18)

Country Link
US (1) US8906895B2 (zh)
EP (1) EP2578574B1 (zh)
JP (1) JP5555320B2 (zh)
KR (2) KR20130111512A (zh)
CN (2) CN104529910B (zh)
AU (1) AU2011259929B2 (zh)
BR (1) BR112012030787A2 (zh)
CA (1) CA2801417C (zh)
EA (1) EA024241B1 (zh)
ES (1) ES2581557T3 (zh)
HK (1) HK1179959A1 (zh)
IL (1) IL223377A (zh)
IN (1) IN2012CN10925A (zh)
MX (1) MX338024B (zh)
PT (1) PT2578574E (zh)
TW (1) TWI492749B (zh)
WO (1) WO2011152508A1 (zh)
ZA (1) ZA201209372B (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012011516A1 (ja) 2010-07-22 2012-01-26 興和株式会社 光学活性１－ブロモ－１－［３，５－ビス（トリフルオロメチル）フェニル］エタンの製造方法
US20130225618A1 (en) * 2010-10-04 2013-08-29 Kowa Co., Ltd. Agent for inhibiting expression of lipid metabolism related mrna
WO2013080999A1 (ja) * 2011-11-29 2013-06-06 興和株式会社 ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤
TW201335109A (zh) * 2011-12-02 2013-09-01 Kowa Co 光學活性化合物之製造方法
JPWO2013137371A1 (ja) * 2012-03-15 2015-08-03 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
WO2014192903A1 (ja) 2013-05-31 2014-12-04 興和株式会社 ジベンジルアミン構造を有するピリミジン化合物の新規形態
US10034892B2 (en) * 2014-08-21 2018-07-31 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN106999491A (zh) * 2014-11-28 2017-08-01 兴和株式会社 医药
WO2016084950A1 (ja) * 2014-11-28 2016-06-02 興和株式会社 医薬組成物
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物
KR20210116548A (ko) * 2019-01-18 2021-09-27 아스트라제네카 아베 Pcsk9 억제제 및 이의 이용 방법
SG11202107615TA (en) 2019-01-18 2021-08-30 Astrazeneca Ab Pcsk9 inhibitors and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189208A (en) 1991-07-01 1993-02-23 Ethyl Corporation Ibuprofen resolution
CN101679309B (zh) * 2007-04-13 2012-02-29 兴和株式会社 具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
US20130225618A1 (en) 2010-10-04 2013-08-29 Kowa Co., Ltd. Agent for inhibiting expression of lipid metabolism related mrna

Also Published As

Publication number Publication date
JPWO2011152508A1 (ja) 2013-08-01
TWI492749B (zh) 2015-07-21
CN102933559A (zh) 2013-02-13
KR20130111512A (ko) 2013-10-10
MX2012014149A (es) 2013-02-27
EP2578574B1 (en) 2016-04-27
TW201208688A (en) 2012-03-01
IN2012CN10925A (zh) 2015-04-24
WO2011152508A1 (ja) 2011-12-08
MX338024B (es) 2016-03-31
AU2011259929A1 (en) 2013-01-17
US20130225814A1 (en) 2013-08-29
US8906895B2 (en) 2014-12-09
ZA201209372B (en) 2014-02-26
JP5555320B2 (ja) 2014-07-23
EP2578574A4 (en) 2013-12-04
EA024241B1 (ru) 2016-08-31
EP2578574A1 (en) 2013-04-10
KR20170078865A (ko) 2017-07-07
CN104529910B (zh) 2017-05-10
EA201291447A1 (ru) 2013-05-30
CA2801417C (en) 2017-07-11
CA2801417A1 (en) 2011-12-08
IL223377A0 (en) 2013-03-05
BR112012030787A2 (pt) 2020-09-01
CN104529910A (zh) 2015-04-22
PT2578574E (pt) 2016-06-17
AU2011259929B2 (en) 2014-07-31
CN102933559B (zh) 2016-01-27
ES2581557T3 (es) 2016-09-06
IL223377A (en) 2016-12-29

Similar Documents

Publication Publication Date Title
HK1179959A1 (zh) 光學活性二苄胺衍生物及其製備方法
EP2610071A4 (en) TIRE AND MANUFACTURING METHOD THEREFOR
PL2552801T3 (pl) Pakowanie, sposób wytwarzania opakowania
EP2647616A4 (en) PROCESS FOR PRODUCING OPTICALLY ACTIVE MENTHOL
EP2610072A4 (en) TIRES AND TIRE MANUFACTURING METHOD
WO2011160196A9 (pt) Método de organização de dados multidimensionais
EP2742993A4 (en) CO2 SUPPORTED TRANSPORT MEMBRANE AND MANUFACTURING METHOD THEREFOR
EP2541563A4 (en) Reactor and method for manufacturing reactor
EP2628400A4 (en) Cigarette and method for manufacturing same
EP2546477A4 (en) COAL POWER PLANT AND OPERATING PROCEDURES FOR THE COAL POWER PLANT
EP2529884A4 (en) Method for manufacturing roller
EP2584602A4 (en) PACKING STRUCTURE, METHOD FOR MANUFACTURING SAME, AND PACKAGING STRUCTURE REPAIR METHOD
EP2634374A4 (en) TURBINE AND METHOD FOR MANUFACTURING TURBINE
IL223583A (en) A method for the production of quinoline-3-carboxamides
EP2570400A4 (en) PROCESS FOR PREPARING -SIALON, -SIALON, AND PRODUCT USING THE SAME
EP2586761A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUORPROPES
EP2608230A4 (en) Capacitor, and method and program for manufacturing same
EP2587499A4 (en) Reactor and reactor manufacturing method
ZA201205650B (en) Manufacturing method for absorbent article
IL222607A0 (en) Method for disinfecting surfaces
EP2587498A4 (en) Reactor and reactor manufacturing method
EP2709127A4 (en) BELLOWS AND METHOD OF MANUFACTURING THE SAME
EP2474516A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUORPROPES
EP2529714A4 (en) MANUFACTURING METHOD FOR ABSORBENT ARTICLES
EP2613657A4 (en) SOCKS, AND SYSTEM AND METHOD FOR MANUFACTURING SOCKS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200530